Founded in 2022, ImmunAdd, Inc., is a privately held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation.
ImmunAdd aims to develop next generation adjuvants which are designed to provide better immune-activities in combining with various vaccines and to have better tolerability.
We are seeking partners with whom we can co-develop our adjuvants and vaccines
Technology
Our proprietary
next generation
saponin-based adjuvant
IA-05 is a truncated QS-21 analogue with improved tolerability, stability, and long-term immune responses in combination of various antigens. IA-05 is expected to lead novel utilities in development of immunotherapies and therapeutic vaccines.
About
ImmunAdd at a glance
ImmunAdd Inc. was established in 2022 as a start-up biotechnology company from National Taiwan University, founded by Professor Pi-Hui Liang and scientists with years of experience in pharmaceutical and industrial sectors.
